Analysts Offer Predictions for Arvinas FY2029 Earnings

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Investment analysts at Wedbush issued their FY2029 earnings estimates for shares of Arvinas in a note issued to investors on Tuesday, February 11th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($1.15) for the year. Wedbush currently has a "Outperform" rating and a $57.00 target price on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.22) per share.

A number of other research firms also recently commented on ARVN. Barclays decreased their price objective on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Oppenheimer upped their price target on Arvinas from $40.00 to $45.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Stifel Nicolaus reduced their price objective on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a report on Wednesday, February 12th. Guggenheim reissued a "buy" rating and issued a $57.00 target price on shares of Arvinas in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Thirteen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $60.00.

Arvinas Stock Performance

Arvinas stock traded up $0.64 during midday trading on Thursday, reaching $18.31. The company's stock had a trading volume of 935,305 shares, compared to its average volume of 823,758. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The stock's 50 day simple moving average is $18.88 and its 200 day simple moving average is $23.16. The firm has a market capitalization of $1.26 billion, a PE ratio of -3.92 and a beta of 1.88.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. During the same quarter last year, the company posted ($2.53) earnings per share.

Hedge Funds Weigh In On Arvinas

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Arvinas by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company's stock valued at $135,389,000 after buying an additional 56,561 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Arvinas by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock valued at $78,656,000 after acquiring an additional 249,295 shares during the last quarter. FMR LLC increased its stake in Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company's stock valued at $71,023,000 after purchasing an additional 204,317 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after acquiring an additional 367,343 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Arvinas during the 4th quarter valued at about $42,332,000. Institutional investors and hedge funds own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.